​

OnKure Therapeutics Stock (NASDAQ:OKUR)

OwnershipFinancialsChart
OnKure Therapeutics by TradingView

Previous Close

$3.57

52W Range

$1.70 - $17.84

50D Avg

$2.76

200D Avg

$3.37

Market Cap

$45.06M

Avg Vol (3M)

$110.01K

Beta

0.43

Div Yield

-

OKUR Company Profile

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

46

IPO Date

-

Website

OKUR Performance

OKUR Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-54.39M$-36.93M$-29.77M
Net Income$-52.67M$-35.31M$-29.51M
EBITDA$-51.71M$-34.75M$-29.38M
Basic EPS-$-2.65$-2.21
Diluted EPS-$-2.65$-2.21

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
NCNANuCana plc
MURAMural Oncology plc
EYENEyenovia, Inc.
JSPRJasper Therapeutics, Inc.
LVTXLAVA Therapeutics N.V.
VRCAVerrica Pharmaceuticals Inc.
RANIRani Therapeutics Holdings, Inc.
XLOXilio Therapeutics, Inc.
GBIOGeneration Bio Co.
PSTVPlus Therapeutics, Inc.